Sponsors
The bill expands life‑saving naloxone access, training, and overdose surveillance in schools—targeting high‑need communities and improving data for responders and policymakers—but relies on short one‑year grants and new reporting/administrative requirements that may strain schools (especially small or private ones), raise privacy concerns, and create questions about long‑term funding and equity.
Students and school staff: Gain access to FDA‑approved opioid overdose reversal medication (naloxone) kept in schools for immediate emergency use, increasing chances of preventing fatal overdoses.
Students, school staff, and families: Schools receive funds and materials to develop CPR, overdose‑response, and prevention programs, improving preparedness and likely reducing youth and community overdose deaths.
First responders, public‑health agencies, schools, and policymakers: Standardized and timelier reporting of naloxone distributions (including integration with NEMSIS/ODMAP) plus grant reporting creates better surveillance and data to guide local response, resource allocation, and future policy.
Schools and students: Grants are limited to one year, risking program and supply discontinuation when funding ends and creating sustainability gaps for naloxone stock and training.
Schools, LEAs, and staff: Application, plan development, and required reporting (including 90‑day submission requirements) create administrative burdens that can strain staff time and local health department capacity.
Small, private, and low‑resource schools: May face technical, staffing, and cost barriers to apply for grants and meet reporting/integration requirements, limiting their ability to participate and worsening inequities.
Based on analysis of 3 sections of legislative text.
Creates one-year competitive grants for K–12 schools/LEAs to buy FDA-approved opioid overdose reversal drugs and run training, and requires federally funded schools to report any distributions to NEMSIS and ODMAP.
Provides one-year competitive federal grants to private K–12 schools, local educational agencies (including charter LEAs), or consortia so they can buy FDA-approved opioid overdose reversal drugs and develop/implement training and emergency response plans. Requires schools and LEAs that receive federal funds to report any distribution of an opioid overdose reversal drug to two national overdose/EMS data systems and sets reporting timelines for grantees and HHS.
Introduced March 19, 2026 by Raul Ruiz · Last progress March 19, 2026